Business Wire

SISVEL

9.5.2024 11:41:30 CEST | Business Wire | Press release

Share
Nordic and Sisvel to Streamline Cellular IoT SEP Licensing

A new agreement between Nordic Semiconductor and patent pool administrator Sisvel for the licensing of standard essential patents (SEPs) reading on LTE-M and NB-IoT cellular technology has been announced. The agreement creates a framework for easy and transparent access to the LTE-M and NB-IoT radio technology standards for a diverse range of IoT applications.

Specifically, the initiative provides a simple, efficient way for IoT device makers to obtain end-product licences from more than 30 patent owners holding LTE-M and NB-IoT SEPs, through Nordic as the cellular module supplier.

The agreement addresses the challenges posed by the diversity within the cellular IoT market, in which a multitude of companies - from startups to established corporations - are innovating. The wide range of significant initiatives being rolled out in areas such as smart-health, smart-energy, smart-cities and asset-tracking are currently at risk of stalling because of the lack of predictability and transparency in the access to and the cost of SEP licensing.

By offering standardised licences the agreement will reduce business uncertainty and the possibility of litigation. This will allow companies to focus on what they do best - developing new, innovative products and services for the IoT market.

"Nordic Semiconductor has always been at the forefront of wireless technology and we understand the importance of accessible and standardised licensing for the advancement of the IoT industry," comments Øyvind Birkenes, Nordic’s EVP Long Range. "We believe that this solution is a significant step towards a more efficient future for cellular IoT development."

"We are thrilled to have a unique licensing programme for cellular IoT backed by more than 30 patent owners and we believe this new agreement with Nordic addresses a critical need in the IoT ecosystem," says Sisvel CEO Mattia Fogliacco. "Our goal is to create a balanced and transparent licensing environment that supports innovation and growth for all stakeholders."

“We have worked hard with Sisvel and the SEP owners in its pool over the last year to broker this agreement because the IoT market urgently needs transparency and predictability,” says Kristian Sæther, Nordic’s Product Director – Cellular IoT. “Existing SEP licensing in the IoT space is up-in-the-air, putting countless SMEs across the globe developing wireless products in limbo. This new agreement offers efficiency and predictability to our customers. We look forward to seeing our peers and competitors recognise the importance of this work, and joining the pool solution, so that the entire cellular IoT market can operate with more predictability, and on a level playing field.”

About Sisvel

Sisvel is driven by a belief in the importance of collaboration, ingenuity and efficiency to bridge the needs of patent owners and those who wish to access their technologies. In a complex and constantly evolving marketplace, our guiding principle is to create a level playing field with the development and implementation of flexible, accessible, commercialisation solutions.

www.sisvel.com

About Nordic Semiconductor

Nordic Semiconductor is a complete end-to-end wireless connectivity solutions provider, with a world-leading position in Bluetooth Low Energy, and an emerging leader in Cellular IoT, NR+, and Wi-Fi wireless technologies, Matter, Thread, Zigbee, and power management. The company’s low power wireless solutions enable millions of IoT devices to connect. Using Nordic’s innovation, its customers and partners across the globe are changing societies and lives for the better by powering smarter, safer, and more sustainable solutions. Nordic’s world-class hardware, software, and development tools are amongst the most advanced in the world, and the company deliver a complete developer experience by offering ultra-low power wireless solutions that are easy to implement, with the best possible support.

www.nordicsemi.com

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240509154129/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release

The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod

JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release

JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu

TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release

TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it

Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release

A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release

Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye